JP2023509462A - チオレドキシン活性を有する組成物および関連方法 - Google Patents

チオレドキシン活性を有する組成物および関連方法 Download PDF

Info

Publication number
JP2023509462A
JP2023509462A JP2022541283A JP2022541283A JP2023509462A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2022541283 A JP2022541283 A JP 2022541283A JP 2022541283 A JP2022541283 A JP 2022541283A JP 2023509462 A JP2023509462 A JP 2023509462A
Authority
JP
Japan
Prior art keywords
thioredoxin
protein
active site
composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541283A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021138682A5 (https=
JP2023509462A5 (https=
Inventor
ビー ハイフェッツ，ピーター
モスコウィッツ，ハイム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orpro Therapeutics inc
Original Assignee
Orpro Therapeutics inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orpro Therapeutics inc filed Critical Orpro Therapeutics inc
Publication of JP2023509462A publication Critical patent/JP2023509462A/ja
Publication of JPWO2021138682A5 publication Critical patent/JPWO2021138682A5/ja
Publication of JP2023509462A5 publication Critical patent/JP2023509462A5/ja
Priority to JP2025116559A priority Critical patent/JP2025182217A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
JP2022541283A 2020-01-03 2021-01-04 チオレドキシン活性を有する組成物および関連方法 Pending JP2023509462A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116559A JP2025182217A (ja) 2020-01-03 2025-07-10 チオレドキシン活性を有する組成物および関連方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956994P 2020-01-03 2020-01-03
US62/956,994 2020-01-03
PCT/US2021/012109 WO2021138682A1 (en) 2020-01-03 2021-01-04 Compositions having thioredoxin activity and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116559A Division JP2025182217A (ja) 2020-01-03 2025-07-10 チオレドキシン活性を有する組成物および関連方法

Publications (3)

Publication Number Publication Date
JP2023509462A true JP2023509462A (ja) 2023-03-08
JPWO2021138682A5 JPWO2021138682A5 (https=) 2024-08-27
JP2023509462A5 JP2023509462A5 (https=) 2024-08-27

Family

ID=76687128

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541283A Pending JP2023509462A (ja) 2020-01-03 2021-01-04 チオレドキシン活性を有する組成物および関連方法
JP2025116559A Pending JP2025182217A (ja) 2020-01-03 2025-07-10 チオレドキシン活性を有する組成物および関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116559A Pending JP2025182217A (ja) 2020-01-03 2025-07-10 チオレドキシン活性を有する組成物および関連方法

Country Status (6)

Country Link
US (1) US20230071765A1 (https=)
EP (1) EP4084867A4 (https=)
JP (2) JP2023509462A (https=)
CN (1) CN115315292A (https=)
CA (1) CA3163157A1 (https=)
WO (1) WO2021138682A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168290B2 (en) 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
AU2021298391A1 (en) * 2020-06-23 2023-02-02 Panasonic Intellectual Property Management Co., Ltd. Method of inactivating allergen and allergen inactivation device
EP4553160A1 (en) * 2022-07-05 2025-05-14 Tohoku University Antiviral agent, pharmaceutical composition for treating or preventing viral infection, kit for evaluating risk of viral infection becoming severe, and method for evaluating risk of viral infection becoming severe

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61282098A (ja) * 1985-04-27 1986-12-12 ベ−リンガ−　インゲルハイム　インタ−ナシヨナル　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツンク α−インタ−フエロンの製造方法
JPH10191977A (ja) * 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
JPH11322631A (ja) * 1998-03-20 1999-11-24 Takeda Chem Ind Ltd 生理活性ポリペプチドの徐放性製剤およびその製造法
JP2014516967A (ja) * 2011-05-17 2014-07-17 ザ リージェント オブ ザ ユニバーシティー オブ コロラド、ア ボディー コーポレート 耐熱性ワクチン組成物及びそれを調製する方法
JP2016517446A (ja) * 2013-03-15 2016-06-16 オアプロ セラピューティクス インコーポレイテッドＯｒｐｒｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 粘液の粘性の正常化のための製品及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148057A1 (en) * 2002-08-02 2006-07-06 Wang Min Thioredoxin mutants and uses thereof
US20090075871A2 (en) * 2003-03-31 2009-03-19 National Institute Of Advanced Industrial Science And Technology Modified Thioredoxin
US20090203586A1 (en) * 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
US20210213134A1 (en) * 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61282098A (ja) * 1985-04-27 1986-12-12 ベ−リンガ−　インゲルハイム　インタ−ナシヨナル　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツンク α−インタ−フエロンの製造方法
JPH10191977A (ja) * 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
JPH11322631A (ja) * 1998-03-20 1999-11-24 Takeda Chem Ind Ltd 生理活性ポリペプチドの徐放性製剤およびその製造法
JP2014516967A (ja) * 2011-05-17 2014-07-17 ザ リージェント オブ ザ ユニバーシティー オブ コロラド、ア ボディー コーポレート 耐熱性ワクチン組成物及びそれを調製する方法
JP2016517446A (ja) * 2013-03-15 2016-06-16 オアプロ セラピューティクス インコーポレイテッドＯｒｐｒｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 粘液の粘性の正常化のための製品及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PDB 3KD0, vol. version 1.3, JPN6024042527, 2010, ISSN: 0005442787 *
QIN J. ET AL., STRUCTURE, vol. Vol. 3, Issue 3, JPN6024042526, 1995, pages 289 - 297, ISSN: 0005442788 *

Also Published As

Publication number Publication date
CN115315292A (zh) 2022-11-08
CA3163157A1 (en) 2021-07-08
US20230071765A1 (en) 2023-03-09
JP2025182217A (ja) 2025-12-12
WO2021138682A1 (en) 2021-07-08
EP4084867A4 (en) 2024-01-24
EP4084867A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
JP2025182217A (ja) チオレドキシン活性を有する組成物および関連方法
US20260027189A1 (en) Product and process for mucus viscosity normalization
US9289471B2 (en) Product and process for liquefaction of mucus or sputum
EP3900735A1 (en) Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor
PT2621515T (pt) Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
WO2017054590A1 (zh) 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
WO2022095973A1 (zh) 尿酸氧化酶制剂及其应用
HK40081004A (en) Compositions having thioredoxin activity and related methods
CN108434439B (zh) 钙网蛋白的医药用途
KR20200078414A (ko) 인슐린 및 글루카곤을 포함하는 약학 조성물
US20220193208A1 (en) Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
KR20100134025A (ko) 뇌막염에 대한 방어소의 용도
HK1220354B (en) Product and process for mucus viscosity normalization
HK40060818A (en) Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor
NZ711983B2 (en) Product and process for mucus viscosity normalization
WO2011034131A1 (ja) 炎症性腸疾患の予防又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231225

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231225

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710